Lead Compound

Type: Keyphrase

Name: Lead Compound

First reported 19 hours ago - Updated 19 hours ago - 1 reports

AtheroNova Mentioned by Analyst in Life Sciences Report

PK:AHRO / NYSE:PFE / NYSE:MRK05/24/2013 [ACCESSWIRE] Mont Blanc Capital Equity Research issued a research update on May 14, 2013 for AtheroNova Inc. (OTC Markets: AHRO). In the report, the analyst maintained its Buy rating and $2.00 per share price target, ... [Published BayStreet.ca - 19 hours ago]

Entities: AtheroNova Inc, Life Science, Phase I, New York Stock Exchange, Coronary Artery Disease

First reported May 23 2013 - Updated May 24 2013 - 1 reports

Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients

"The initiation of this clinical trial is an important milestone for our Company," said Doug Jensen"Unlike other classes of drugs for HCV infection that act directly on the virus, SB 9200 targets host cytosolic sensor proteins, RIG-I and NOD2," states ... [Published Street Insider - May 23 2013]

Entities: Spring Bank Pharmaceuticals Inc, Patient, Chronic Obstructive Pulmonary Disease, Small Molecule Nucleic Hybrid

First reported May 23 2013 - Updated May 23 2013 - 1 reports

Drug dependency research wins PhD students prizes

PhD students from the Department of Pharmacy & Pharmacology researching new ways to prevent relapse in people with an opiate or cocaine dependency won prizes at this year’s European Opioid Conference.Sarah Cordery was awarded the prize for best oral presentation ... [Published University of Bath - May 23 2013]

Entities: opiate, Drugs, Cocaine, Naltrexone, Buprenorphine

First reported May 23 2013 - Updated May 23 2013 - 1 reports

Improved Purification Of Lead Generation Compounds By Flash Chromatography

During pharmaceutical development of biologically active compounds, the identification and purification of unknown impurities is a key requirement for the successful registration of a new molecular entity. Traditional flash chromatography, as preferred ... [Published Food Online - May 23 2013]

Entities: Chromatography, Impurity, Lead Compound

First reported May 21 2013 - Updated May 21 2013 - 1 reports

University of Connecticut

Connecticut Innovations Commits $560,000 to Bioscience and Medical Device Startups

– Connecticut Innovations (CI), the state’s quasi-public authority responsible for growing Connecticut businesses through innovative financing and strategic assistance, today announced that it has committed funding totaling $560,000 through its Pre-Seed ... [Published Connecticut Innovations - May 21 2013]

Entities: Connecticut Innovations, LambdaVision Inc, University of Connecticut, BIOARRAY Therapeutics

First reported May 21 2013 - Updated May 21 2013 - 1 reports

Phytopharm Plc

Phytopharm delists in anticipation of reverse takeover

Shares in drug discovery firm, Phytopharm, ceased trading today as the biotech announced it is to seek shareholder approval for a reverse takeover with an unnamed UK healthcare company.Phytopharm suffered what was effectively a knockout blow in February ... [Published Cabume - May 21 2013]

Entities: Phytopharm Plc, Lead Compound, Hoodia, Unilever Group, Placebo

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer

Flexion Therapeutics, Inc. today announced the addition of Frederick W. Driscoll to its management team as chief financial officer. Mr. Driscoll has more than 30 years of financial management experience with biotechnology and medical device companies ... [Published Zecco - May 20 2013]

Entities: Flexion Ltd, Therapeutics, Novavax Inc, Osteoarthritis

First reported May 09 2013 - Updated May 09 2013 - 1 reports

Unigene and Nordic Bioscience Enter Equity Transfer and Exclusive License Agreement for Proprietary Metabolic Peptide Analogs

BOONTON, N.J.Under the terms of the equity transfer and exclusive license agreement, Nordic has agreed to pay $1,000,000 for Unigene's ownership interest in the JDV. In accordance, Unigene has granted the now 100% Nordic owned JDV, an exclusive, royalty-bearing ... [Published Bio-Medicine - May 09 2013]

Entities: Nordic Bioscience, Exclusive License, Peptide

First reported May 06 2013 - Updated May 06 2013 - 1 reports

Concert Pharma teams up with Celgene, signs third agreement in a year

Concert Pharmaceuticals, a clinical stage biotech company focused on small molecule drugs in the area of renal disease, blood and central nervous system disorders, and other therapeutic areas, has agreed to collaborate with Summit, N.J.-based Celgene ... [Published Boston Business Journal - May 06 2013]

Entities: Concert Pharmaceuticals Inc, Celgene Corporation, Lead Compound, Central Nervous System, Drugs

First reported May 06 2013 - Updated May 06 2013 - 1 reports

NeuroPhage, backed by Michael J. Fox Foundation, raises $6.4M more

PrintEmail Comments (0)NeuroPhage Pharmaceuticals Inc., a Cambridge-based company that develops therapies for neurodegenerative diseases, said today it has raised $6.4 million in a private-equity financing round.Merieux Developpment led the funding with ... [Published Boston Herald - May 06 2013]

Entities: Michael J. Fox Foundation, alpha-synuclein, Protein, Lead Compound

First reported May 03 2013 - Updated May 03 2013 - 1 reports

Soligenix narrows Q1 loss as revenues increase, expenses decline; drug development continues

Soligenix (OTCQB:SNGX) said Friday that it narrowed its net loss in the first quarter as revenues increased and operating expenses declined, as the company says it continues to make progress in both its biotherapeutics and biodefense businesses. ... [Published Proactiveinvestors United Kingdom RSS feed - May 03 2013]

Entities: Biological Defense, Vaccine, gastrointestinal, Drugs, Operating Expenses

First reported May 01 2013 - Updated May 01 2013 - 1 reports

Clinuvel Pharmaceuticals heads to market

Clinuvel Pharmaceuticals (ASX: CUV; XETRA‐DAX: UR9; ADR: CLVLY) has been granted a trading halt this morning, with its shares placed in pre-open, pending the release of capital raising details.The biopharmaceutical company is focused on developing drugs ... [Published Proactive Investors Australia - May 01 2013]

Entities: Clinuvel Pharmaceuticals Ltd, Australian Securities Exchange, Lead Compound, Australia, DAX Index

Quotes

...for novel antibiotic therapies for the treatment of resistant pathogens in respiratory disease in the critical care setting," said Aaron Davidson. "As a new member of the board of directors, I look forward to working with the Cardeas management team to advance phase II efforts for their first development program."

Cardeas Pharma completes $34M in Series B financing [Published Center Watch - 9 hours ago]

"Unlike other classes of drugs for HCV infection that act directly on the virus, SB 9200 targets host cytosolic sensor proteins, RIG-I and NOD2" states Dr...

Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients [Published Street Insider - May 23 2013]

...Kris Iyer, CSO and Co-founder of Spring Bank. "This leads to the selective activation of the host immune response in the presence of viral infection." By way of its novel mechanism of action, SB 9200 is ideally suited for combination with other classes of HCV antivirals, including direct-acting antiviral...

Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients [Published Michigan Live - May 23 2013]

Dr Nozer Mehta, Chief Scientific Officer for Unigene stated, "We have been extremely pleased with our collaboration with Nordic Bioscience. The synergy between the capabilities of our two companies has allowed us to progress very rapidly with this exciting program. By way of the original JDV, Nordic has been able to expedite its evaluation of the Unigene peptides and has successfully used its industry-leading know-how and experience to determine their efficacy using a variety of cell-based technologies and animal models."

Unigene enters into license agreement with Nordic for three peptide analogs [Published Zecco - May 23 2013]

More Content

sort by: Date \| Relevance
Cardeas Pharma completes $34M in Series B finan... [Published Center Watch - 9 hours ago]
AtheroNova Mentioned by Analyst in Life Science... [Published BayStreet.ca - 19 hours ago]
Cardeas Pharma raises $34 million Series B roun... [Published Individual.com - May 23 2013]
Cardeas Pharma Completes $34 Million in Series ... [Published FierceBiotech - May 23 2013]
Drug dependency research wins PhD students prizes [Published University of Bath - May 23 2013]
Spring Bank Pharmaceuticals Initiates a Phase I... [Published Street Insider - May 23 2013]
Spring Bank Pharmaceuticals Initiates a Phase I... [Published Michigan Live - May 23 2013]
Spring Bank Pharmaceuticals Initiates a Phase I... [Published PR Newswire - May 23 2013]
Unigene enters into license agreement with Nord... [Published Zecco - May 23 2013]
Improved Purification Of Lead Generation Compou... [Published Food Online - May 23 2013]
Soligenix gets key Thermovax technology U.S. pa... [Published Proactive Investors.co.uk - May 22 2013]
Soligenix gets key Thermovax technology U.S. pa... [Published Proactiveinvestors United Kingdom RSS feed - May 22 2013]
Soligenix gets key Thermovax technology U.S. pa... [Published Proactiveinvestors United Kingdom RSS feed - May 22 2013]
Soligenix gets key Thermovax technology U.S. pa... [Published Proactive Investors USA - May 22 2013]
Cleveland BioLabs to Present at Second Annual M... [Published Barchart - May 22 2013]
OTC Signal Daily Stock Watch - RTRX [Published Individual.com - May 21 2013]
Phytopharm delists in anticipation of reverse t... [Published Cabume - May 21 2013]
Oncopeptides Secures Venture Funding for Phase ... [Published PR Newswire - May 21 2013]
Anavex Life Sciences Corp. (AVXL) - Pharmaceuti... [Published TransWorldNews - May 21 2013]
Connecticut Innovations Commits $560,000 to Bio... [Published Connecticut Innovations - May 21 2013]
AB SCIENCE: Launch of a phase 3 clinical trial ... [Published 4 Traders - May 20 2013]
Catalyst Pharmaceutical's CPP-115 May Be Big Pi... [Published Seeking Alpha - May 20 2013]
AB Science : Launch of a phase 3 clinical trial... [Published Reuters - May 20 2013]
Asmacure Highlights Four Presentations on Novel... [Published FinanzNachrichten.de - May 20 2013]
Flexion Therapeutics Names Frederick Driscoll C... [Published Zecco - May 20 2013]
Insero Health announces topline results from ph... [Published PharmaBiz - May 20 2013]
Deals Of The Week Is Keeping Score – Valeant Wa... [Published The IN VIVO Blog - May 17 2013]
Financings of the Fortnight Waits For Public In... [Published The IN VIVO Blog - May 17 2013]
Insero Health Reports Positive Data on Phase I ... [Published FinanzNachrichten.de - May 17 2013]
Insero Health Reports Positive Data on Phase I ... [Published PR Newswire: Health - May 17 2013]

sort by: Date \| Relevance
Deals Of The Week Is Keeping Score – Valeant Wa... [Published The IN VIVO Blog - May 17 2013] Whether the pastime is baseball, Broadway or the daytime soaps, the old adage is that you can’t keep track of the players without a scorecard. The M&A front involving specialty pharma and generic drug makers has become similarly frenzied, as Canada’s ...
Financings of the Fortnight Waits For Public In... [Published The IN VIVO Blog - May 17 2013] It’s been another IPO-intensive couple of weeks here at FOTF HQ. We keep looking for other things to write about, but sometimes the fastest shave on deadline is with Occam’s razor. Or something like that. We didn't exactly ace our philosophy classes ...
Deals of the Week: With Option Deal, Forest Kee... [Published The IN VIVO Blog - May 10 2013] It’s an optimistic time for pharma dealmakers, with the Dow and the Nasdaq Biotechnology Index climbing, buyers sitting on big piles of cash, and the IPO window as wide-open as it’s been in years. But for smaller companies that have long lamented that ...
Proteros and Eisai Achieve Target in Lead Disco... [Published Pharma-Mag - May 09 2013] Proteros Biostructures GmbH announced the successful completion of an integrated lead discovery collaboration with Eisai Co., Ltd. Based on Proteros’ structure guided discovery platform, various series of Lead Compounds were developed within a period ...
Proteros and Eisai Achieve Target in Lead Disco... [Published Pharma-Mag - May 08 2013] Proteros biostructures GmbH has announced the successful completion of an integrated lead discovery collaboration with Eisai Co., Ltd. Based on Proteros’ structure guided discovery platform, various series of Lead Compounds were developed within a period ...